BEIJING, Nov. 20, 2024 /PRNewswire/ — So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the third quarter ended September 30, 2024.

Third Quarter 2024 Financial Highlights

Total revenues were RMB371.8 million (US$53.0 million[1]), compared with RMB385.3 million in the corresponding period of 2023, exceeding the high end of guidance.Net income attributable to So-Young International Inc. was RMB20.3 million (US$2.9 million), compared with net income attributable to So-Young International Inc. of RMB18.3 million in the same period of 2023.Non-GAAP net income attributable to So-Young International Inc.[2] was RMB22.2 million (US$3.2 million), compared with non-GAAP net income attributable to So-Young International Inc. of RMB9.5 million in the same period of 2023.

Third Quarter 2024 Operational Highlights

Average mobile MAUs were 1.4 million, compared with 3.1 million in the third quarter of 2023.Number of medical service providers subscribing to information services on So-Young’s platform was 1,322, compared with 1,397 in the third quarter of 2023.Total number of purchasing users through reservation services was 114.9 thousand and the aggregate value of medical aesthetic treatment transactions facilitated by So-Young’s platform was RMB346.0 million.

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, said, “Our third quarter performance beat the high end of our guidance once again, highlighting the resilience of our business. Sales of medical products and maintenance services grew by 18.7% year-over-year, becoming a key growth driver contributing to a year-over-year increase in net income. This underscores the effectiveness of our strategy to stay at the forefront of industry trends by deepening the synergies from our vertical integration and continuously diversifying our offerings. Our clinic network has experienced significant growth. The number of stores has grown to 16 by the end of this quarter, extending our presence into additional major cities. All stores are situated in central business districts, enhancing our market coverage and competitive position. To further scale our offline presence, we are accelerating the deployment of this proven standardized model in other cities nationwide and are exploring franchising opportunities to engage with a wider audience. The reputational strength of our brand and our deep understanding of evolving consumer behavior uniquely position us to develop products that resonate with consumer needs. Sales momentum remains robust, driven by both our well-established products and exciting new launches in collaboration with our supply chain partners. Looking ahead, we are committed to seizing opportunities across the entire medical aesthetics value chain while deepening the integration of our three core businesses to maximize operational efficiency, customer satisfaction, and sustainable growth.”

Mr. Hui Zhao, Chief Financial Officer of So-Young, added, “Our third-quarter results reflect our ability to strategically adapt to changing market dynamics. Through disciplined cost management and targeted growth initiatives, we are carefully navigating this challenging market environment while building a solid foundation for future expansion. Encouragingly, our net income and non-GAAP net income attributable to So-Young International Inc. improved significantly, with year-over-year growth rates exceeding 8.9% and 133.1% respectively. Looking ahead, we will leverage our expanding network of clinics and meticulously curated product offerings to address the growing demand for high-quality solutions and services. By maintaining operational efficiency and scalability, we are well-positioned to continue leading the medical aesthetics sector, delivering sustainable growth and long-term value for our shareholders.”

Third Quarter 2024 Financial Results     

Revenues

Total revenues were RMB371.8 million (US$53.0 million), a decrease of 3.5% from RMB385.3 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young’s platform.

Information services and other revenues were RMB263.0 million (US$37.5 million), a decrease of 8.0% from RMB285.9 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young’s platform.Reservation services revenues were RMB19.6 million (US$2.8 million), a decrease of 18.9% from RMB24.1 million in the same period of 2023. The decrease was primarily due to a decrease in consumer spending through our platform.Sales of medical products and maintenance services were RMB89.3 million (US$12.7 million), an increase of 18.7% from RMB75.2 million in the same period of 2023, primarily due to an increase in the order volumes for cosmetic products and medical equipment.

Cost of Revenues

Cost of revenues was RMB142.2 million (US$20.3 million), a decrease of 0.3% from RMB142.6 million in the third quarter of 2023. The decrease was primarily due to a decrease in the cost of services associated with the information services. Cost of revenues included share-based compensation expenses of RMB0.1 million (US$0.0 million), compared with the share-based compensation expenses of RMB0.4 million in the corresponding period of 2023.

Cost of services and others were RMB98.6 million (US$14.1 million), a decrease of 4.7% from RMB103.5 million in the third quarter of 2023. The decrease was primarily due to a decrease in the cost of services associated with the information services.Cost of medical products sold and maintenance services were RMB43.5 million (US$6.2 million), an increase of 11.3% from RMB39.1 million in the third quarter of 2023. The increase was primarily due to an increase in costs associated with the sales of cosmetic products.

Operating Expenses

Total operating expenses were RMB225.0 million (US$32.1 million), a decrease of 8.1% from RMB244.7 million in the third quarter of 2023.

Sales and marketing expenses were RMB114.9 million (US$16.4 million), a decrease of 20.1% from RMB143.8 million in the third quarter of 2023. The decrease was mainly due to a decrease in expenses associated with branding and user acquisition activities. Sales and marketing expenses included share-based compensation expenses of RMB0.2 million (US$0.0 million), compared with RMB0.5 million in the corresponding period of 2023.General and administrative expenses were RMB69.9 million (US$10.0 million), an increase of 39.1% from RMB50.2 million in the third quarter of 2023. The increase was primarily due to an increase in share-based compensation expenses. General and administrative expenses included share-based compensation expenses of RMB1.3 million (US$0.2 million), compared with a reversal of share-based compensation expenses of RMB11.2 million in the corresponding period of 2023.Research and development expenses were RMB40.2 million (US$5.7 million), a decrease of 20.6% from RMB50.6 million in the third quarter of 2023. The decrease was primarily attributable to improvements in staff efficiency. Research and development expenses included share-based compensation expenses of RMB0.3 million (US$0.0 million), compared with RMB1.5 million in the corresponding period of 2023.

Income Tax (Expenses)/Benefits

Income tax expenses were RMB2.1 million (US$0.3 million), compared with income tax benefits of RMB2.2 million in the same period of 2023.

Net Income Attributable to So-Young International Inc.

Net income attributable to So-Young International Inc. was RMB20.3 million (US$2.9 million), compared with a net income attributable to So-Young International Inc. of RMB18.3 million in the third quarter of 2023.

Non-GAAP Net Income Attributable to So-Young International Inc.

Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses attributable to So-Young International Inc., was RMB22.2 million (US$3.2 million), compared with RMB9.5 million non-GAAP net income attributable to So-Young International Inc. in the same period of 2023.

Basic and Diluted Earnings per ADS

Basic and diluted earnings per ADS attributable to ordinary shareholders were RMB0.20 (US$0.03) and RMB0.20 (US$0.03), respectively, compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.18 and RMB0.18, respectively, in the same period of 2023.

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

As of September 30, 2024, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB1,252.6 million (US$178.5 million), compared with RMB1,341.6 million as of December 31, 2023.

Business Outlook

For the fourth quarter of 2024, So-Young expects total revenues to be between RMB350.0 million (US$49.9 million) and RMB370.0 million (US$52.7 million), representing a 10.4% to 5.3% decrease from the same period in 2023. The above outlook is based on the current market conditions and reflects the Company’s preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.

Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP income/(loss) from operations and non-GAAP net income attributable to So-Young International Inc. by excluding share-based compensation expenses from income/(loss) from operations and net income attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company’s operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company’s core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company’s results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company’s performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

Conference Call Information

So-Young’s management will hold an earnings conference call on Wednesday, November 20, 2024, at 7:00 AM U.S. Eastern Time (8:00 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:

A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, November 27, 2024. The dial-in details are:

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

About So-Young International Inc.

So-Young International Inc. (Nasdaq: SY) is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young’s strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young’s strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young’s beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young’s strategies; So-Young’s future business development, financial condition and results of operations; So-Young’s ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young’s revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

So-Young

Investor Relations
Ms. Mona Qiao
Phone: +86-10-8790-2012
E-mail: ir@soyoung.com 

Christensen

In China
Ms. Dee Wang
Phone: +86-10-5900-1548
E-mail: dee.wang@christensencomms.com 

In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: linda.bergkamp@christensencomms.com 

View original content:https://www.prnewswire.com/news-releases/so-young-reports-unaudited-third-quarter-2024-financial-results-302311180.html

SOURCE So-Young International Inc.

LONDON, Nov. 20, 2024 /PRNewswire/ — Cynerio, a leading innovator in healthcare cybersecurity, today announced its recognition among The Healthcare Technology Report’s Top 100 Healthcare Technology Companies for 2024. This distinction highlights Cynerio’s pivotal advancements this year, from its breakthrough innovations in generative AI-driven security to the industry’s first healthcare-specific Network Detection and Response (NDR) solution, positioning Cynerio as the benchmark for effective cybersecurity in healthcare.

2024 has been a transformative year for Cynerio. Amid a rise in healthcare-targeted cyberattacks — now affecting U.S. hospitals at an unprecedented rate of every 7.1 minutes — Cynerio has proactively responded with innovations that prioritize healthcare’s unique security needs. By expanding its solutions beyond medical device security to encompass the entire clinical network, Cynerio has provided healthcare organizations with comprehensive, actionable defenses that protect against ransomware, ensure regulatory compliance, and deliver unmatched visibility into connected device risks.

“Being named to The Healthcare Technology Report’s Top 100 list reflects the tremendous strides Cynerio has made this year,” said Leon Lerman, CEO and Co-Founder of Cynerio. “Our goal has always been to anticipate and outpace the cybersecurity challenges healthcare faces, and this year we’ve not only expanded our geographic footprint but also reshaped what’s possible in healthcare security with new generative AI capabilities and NDR technology specifically tailored to this sector. We’re honored by this recognition, and even more energized to continue our mission in 2025, helping healthcare providers around the world navigate the rising tide of cyber threats.”

This year’s achievements solidify Cynerio’s reputation as the “first mover” in critical healthcare cybersecurity technologies. By integrating generative AI into its platform, Cynerio enables real-time threat detection, rapid incident response, and cross-customer benchmarking — all with the scalability to support healthcare providers worldwide. Cynerio’s cloud-based capabilities and deep focus on healthcare-specific vulnerabilities have resonated with hospitals and healthcare systems globally, driving the company’s footprint across the U.S., Europe, and new regions in 2024.

With the new year on the horizon, Cynerio remains committed to driving the next wave of cybersecurity in healthcare, ensuring that every healthcare facility, regardless of size, has access to innovative tools to combat cyber threats. Looking to 2025, Cynerio plans to build on its platform with additional AI-driven insights, new strategic partnerships, and expanded coverage, empowering healthcare providers to face rising challenges and secure their digital future with confidence.

About Cynerio:

Cynerio’s Healthcare Cybersecurity Platform is tailored to safeguard medical environments against constantly evolving threats. From real-time detection of malicious network activity to strategic micro-segmentation guidance, Cynerio delivers a suite of proactive and reactive protections that elevate the security of healthcare facilities and ensure the safety of patients. For more information visit www.cynerio.com.

Media Contact:
Name: Vicki Michaeli
Email: vicki@cynerio.com

Logo – https://mma.prnewswire.com/media/1876294/Cynerio_Logo_Logov1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/cynerio-recognized-as-top-100-healthcare-technology-companies-of-2024-by-the-healthcare-technology-report-302306199.html

New ODAIA Voice Assistant will allow sales reps to access AI-driven insights in real time using voice commands on mobile devices

BOSTON, Nov. 20, 2024 /PRNewswire/ — ODAIA today announced a new voice AI assistant for biopharma sales teams. ODAIA Voice Assistant will help reps access relevant and accurate AI-driven insights in real time by speaking into their mobile device. Now reps can quickly find healthcare professional (HCP) information on the go, enhance pre-call planning, and get personalized recommendations about which physicians to engage next—all through voice commands instead of typing or clicking.

Sales reps juggle multiple tools to gather insights, including CRM for engagement history, dashboards for prescription and patient information, and business intelligence systems for market analysis. This fragmented workflow slows the last mile of field execution. While some companies now use AI chatbots with their raw data to find information, these tools often deliver inaccurate, incomplete, and unreliable insights that reps can’t act on.

ODAIA solves these limitations with voice AI that goes beyond just raw data. ODAIA’s advanced AI engines generate intelligence on HCP and patient behavior changes, untapped market trends and opportunities, and sales team performance. Large language models (LLMs) then translate these insights into clear, actionable stories that sales reps can easily understand and quickly access with Voice Assistant.

“Voice-first technology will become standard in life sciences”, said Philip Poulidis, CEO at ODAIA. “What makes voice AI valuable is the intelligence it can tap into, not the raw data. With ODAIA Voice Assistant, we’re not just addressing the challenges commercial teams face today but setting the foundation for future voice-first interfaces that transform how sales reps engage with data, make decisions, and deliver meaningful outcomes for providers and patients.”

Speaking is three times faster than typing and more accurate.1 But most generic AI chatbots and standard GenAI tools slow users down and frustrate them because of the technology’s failed attempts to make sense of raw data and its need for precise phrasing and repeated corrections. Voice Assistant solves this problem with voice AI technology purpose-built for biopharma, delivering accurate and relevant insights through natural conversations.

Voice Assistant is powered by MAPTUAL, ODAIA’s proprietary platform of AI engines specifically designed for the biopharma industry. MAPTUAL uses a modular approach to analyze complex datasets and provide real-time insights into a physician’s changing behaviors, prescribing trends, and potential brand impact. Voice Assistant taps into these insights and uses GenAI to go beyond surface-level responses and dynamically adapt during conversations, offering personalized, relevant guidance that enhances HCP engagement.

ODAIA Voice Assistant is expected to be available for early adopters in the second quarter of 2025. To learn how to be an early adopter, visit: www.odaia.ai/voice-assistant.

Also, see how ODAIA Voice Assistant will enable the biopharma industry’s shift to voice AI at our Innovation Theater Session during Veeva Commercial Summit Europe on Nov. 21 at 10:00 a.m. CET. CEO Philip Poulidis will demonstrate how to plan daily schedules, personalize interactions with HCPs, and make informed decisions using ODAIA integrated with Veeva Vault CRM. To meet with ODAIA, book a meeting here.

About ODAIA
ODAIA is the leading AI company helping life sciences companies innovate their commercial strategies using Customer Science. The company’s cloud solution, MAPTUAL, integrates data science, behavioral science, and AI to gain a deep understanding of healthcare professionals (HCPs) and their patient decisions across the entire customer journey. To learn more about ODAIA, visit our website or follow us on LinkedIn.

1 https://faculty.washington.edu/wobbrock/pubs/ubicomp-17.pdf

View original content to download multimedia:https://www.prnewswire.com/news-releases/odaia-announces-voice-ai-for-biopharma-to-advance-healthcare-professional-engagement-302310954.html

SOURCE ODAIA